168 related articles for article (PubMed ID: 26632716)
1. Expression of LRIG1 is Associated With Good Prognosis for Human Non-small Cell Lung Cancer.
An Y; Zhao Z; Ou P; Wang G
Medicine (Baltimore); 2015 Nov; 94(47):e2081. PubMed ID: 26632716
[TBL] [Abstract][Full Text] [Related]
2. LRIG1 is a prognostic biomarker in non-small cell lung cancer.
Kvarnbrink S; Karlsson T; Edlund K; Botling J; Lindquist D; Jirström K; Micke P; Henriksson R; Johansson M; Hedman H
Acta Oncol; 2015; 54(8):1113-9. PubMed ID: 25813475
[TBL] [Abstract][Full Text] [Related]
3. LRIG and cancer prognosis.
Lindquist D; Kvarnbrink S; Henriksson R; Hedman H
Acta Oncol; 2014 Sep; 53(9):1135-42. PubMed ID: 25180912
[TBL] [Abstract][Full Text] [Related]
4. LMO7 and LIMCH1 interact with LRIG proteins in lung cancer, with prognostic implications for early-stage disease.
Karlsson T; Kvarnbrink S; Holmlund C; Botling J; Micke P; Henriksson R; Johansson M; Hedman H
Lung Cancer; 2018 Nov; 125():174-184. PubMed ID: 30429017
[TBL] [Abstract][Full Text] [Related]
5. Leucine-rich repeats and immunoglobulin-like domains protein 1 and fascin actin-bundling protein 1 expression in nonsmall cell lung cancer.
Zhang J; Wang X; Zhang Y; Wu J; Zhou N
J Cancer Res Ther; 2016 Dec; 12(Supplement):C248-C251. PubMed ID: 28230028
[TBL] [Abstract][Full Text] [Related]
6. Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer.
Liu J; Ping W; Zu Y; Sun W
Int J Clin Exp Pathol; 2014; 7(9):6040-7. PubMed ID: 25337249
[TBL] [Abstract][Full Text] [Related]
7. A novel molecular staging protocol for non-small cell lung cancer.
Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
[TBL] [Abstract][Full Text] [Related]
8. Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.
Torigoe H; Yamamoto H; Sakaguchi M; Youyi C; Namba K; Sato H; Shien K; Soh J; Suzawa K; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
Carcinogenesis; 2018 May; 39(5):719-727. PubMed ID: 29546323
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer.
Chen DT; Hsu YL; Fulp WJ; Coppola D; Haura EB; Yeatman TJ; Cress WD
J Natl Cancer Inst; 2011 Dec; 103(24):1859-70. PubMed ID: 22157961
[TBL] [Abstract][Full Text] [Related]
10. LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix.
Hedman H; Lindström AK; Tot T; Stendahl U; Henriksson R; Hellberg D
Acta Oncol; 2010 Aug; 49(6):812-5. PubMed ID: 20553099
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer.
Yang J; Liu H; Wang H; Sun Y
Pathol Res Pract; 2013 Aug; 209(8):490-4. PubMed ID: 23827213
[TBL] [Abstract][Full Text] [Related]
12. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
13. Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma.
Muller S; Lindquist D; Kanter L; Flores-Staino C; Henriksson R; Hedman H; Andersson S
Int J Oncol; 2013 Jan; 42(1):247-52. PubMed ID: 23165628
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and prognostic significance of microRNA-107 in human non small cell lung cancer.
Zhong KZ; Chen WW; Hu XY; Jiang AL; Zhao J
Int J Clin Exp Pathol; 2014; 7(7):4545-51. PubMed ID: 25120851
[TBL] [Abstract][Full Text] [Related]
15. Down-regulated MicroRNA 148b expression as predictive biomarker and its prognostic significance associated with clinicopathological features in non-small-cell lung cancer patients.
Ghasemkhani N; Shadvar S; Masoudi Y; Talaei AJ; Yahaghi E; Goudarzi PK; Shakiba E
Diagn Pathol; 2015 Sep; 10():164. PubMed ID: 26377406
[TBL] [Abstract][Full Text] [Related]
16. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study.
Ahrendt SA; Hu Y; Buta M; McDermott MP; Benoit N; Yang SC; Wu L; Sidransky D
J Natl Cancer Inst; 2003 Jul; 95(13):961-70. PubMed ID: 12837832
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.
Boros A; Lacroix L; Lacas B; Adam J; Pignon JP; Caramella C; Planchard D; de Montpreville V; Deutsch E; Levy A; Besse B; Le Pechoux C
Oncotarget; 2017 Apr; 8(15):25189-25199. PubMed ID: 28445990
[TBL] [Abstract][Full Text] [Related]
19. The associations of TERT-CLPTM1L variants and TERT mRNA expression with the prognosis of early stage non-small cell lung cancer.
Chen Z; Wang J; Bai Y; Wang S; Yin X; Xiang J; Li X; He M; Zhang X; Wu T; Xu P; Guo H
Cancer Gene Ther; 2017 Jan; 24(1):20-27. PubMed ID: 27982019
[TBL] [Abstract][Full Text] [Related]
20. Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer.
Liu Y; Zhang G; Li H; Han L; Fu A; Zhang N; Zheng Y
Biomed Pharmacother; 2015 Oct; 75():185-90. PubMed ID: 26337230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
